High-dose cyclophosphamide for hard-to-treat patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, a phase II result.
bridging therapy
high-dose cyclophosphamide
non-Hodgkin's lymphoma
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
19
10
2019
revised:
05
12
2019
accepted:
11
12
2019
pubmed:
16
12
2019
medline:
15
12
2020
entrez:
16
12
2019
Statut:
ppublish
Résumé
High-dose cyclophosphamide to treat solid refractory tumors demonstrated meaningful activity, while data to treat lymphoma remain scarce. This study aims to assess high-dose cyclophosphamide to treat relapsed or refractory lymphoma. A phase II study included adult patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, previously treated by ≥2 prior lines with no other available option of therapy. High-dose cyclophosphamide was given intravenously 3 g/m Forty-two patients with median age 65 [56-70] years were included. Patients had previously received a median of four lines of therapies. Tumor types were diffuse large B-cell lymphoma (n = 26; 62%), indolent B-cell non-Hodgkin lymphoma (n = 10; 24%), or mantle lymphoma (n = 6; 14%). Hematologic and non-hematologic grade 3-5 toxicities occurred in 42 (100%) and 18 (43%) of patients, respectively. The overall response rate was 45%. One to two cycles of high-dose cyclophosphamide in hard-to-treat patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated a favorable safety and efficacy profile. This regimen could serve as a bridge to modern cellular therapy with CAR-T cell.
Sections du résumé
BACKGROUND
BACKGROUND
High-dose cyclophosphamide to treat solid refractory tumors demonstrated meaningful activity, while data to treat lymphoma remain scarce. This study aims to assess high-dose cyclophosphamide to treat relapsed or refractory lymphoma.
METHODS
METHODS
A phase II study included adult patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, previously treated by ≥2 prior lines with no other available option of therapy. High-dose cyclophosphamide was given intravenously 3 g/m
RESULTS
RESULTS
Forty-two patients with median age 65 [56-70] years were included. Patients had previously received a median of four lines of therapies. Tumor types were diffuse large B-cell lymphoma (n = 26; 62%), indolent B-cell non-Hodgkin lymphoma (n = 10; 24%), or mantle lymphoma (n = 6; 14%). Hematologic and non-hematologic grade 3-5 toxicities occurred in 42 (100%) and 18 (43%) of patients, respectively. The overall response rate was 45%.
CONCLUSION
CONCLUSIONS
One to two cycles of high-dose cyclophosphamide in hard-to-treat patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated a favorable safety and efficacy profile. This regimen could serve as a bridge to modern cellular therapy with CAR-T cell.
Substances chimiques
Antineoplastic Agents, Alkylating
0
Cyclophosphamide
8N3DW7272P
Types de publication
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
281-290Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Mullins GM, Anderson PN, Santos GW. High dose cyclophosphamide therapy in solid tumors. Therapeutic, toxic, and immunosuppressive effects. Cancer. 1975;36(6):1950-1958.
Collins C, Mortimer J, Livingston RB. High-dose cyclophosphamide in the treatment of refractory lymphomas and solid tumor malignancies. Cancer. 1989;63(2):228-232.
Lenhard RE, Oken MM, Barnes JM, et al. High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma. Cancer. 1984;53(7):1456-1460.
Desikan KR, Barlogie B, Jagannath S, et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol. 1998;16(4):1547-1553.
Gettys SC, Gulbis A, Wilhelm K, et al. Modified CVAD and modified CBAD compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma. Eur J Haematol. 2017;98(4):388-392.
Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet Lond Engl. 2002;359(9323):2065-2071.
Emmenegger U, Man S, Shaked Y, et al. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res. 2004;64(11):3994-4000.
Frei E, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med. 1980;69(4):585-594.
Schabel FM, Griswold DP, Corbett TH, Laster WR. Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology. Cancer. 1984;54(6 Suppl):1160-1167.
Santos GW, Sensenbrenner LL, Burke PJ, et al. The use of cyclophosphamide for clinical marrow transplantation. Transplant Proc. 1972;4(4):559-564.
Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009;6(11):638-647.
Smith IE, Evans BD, Harland SJ, Millar JL. Autologous bone marrow rescue is unnecessary after very-high-dose cyclophosphamide. Lancet Lond Engl. 1983;1(8314-5):76-77.
Buckner CD, Rudolph RH, Fefer A, et al. High-dose cyclophosphamide therapy for malignant disease. Toxicity, tumor response, and the effects of stored autologous marrow. Cancer. 1972;29(2):357-365.
Tuchman SA, Bacon WA, Huang L-W, et al. Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. J Clin Apheresis. 2015;30(3):176-182.
Gamper CJ, Takemoto CM, Chen AR, et al. High-dose cyclophosphamide is effective therapy for pediatric severe aplastic anemia. J Pediatr Hematol Oncol. 2016;38(8):627-635.
Schmitz N, Nickelsen M, Ziepert M, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012;13(12):1250-1259.
Souhami RL, Finn G, Gregory WM, et al. High-dose cyclophosphamide in small-cell carcinoma of the lung. J Clin Oncol: Off J Am Soc Clin Oncol. 1985;3(7):958-963.
Geisler HE, Minor JR, Eastlund ME. The treatment of advanced ovarian carcinoma with high dose, intravenous cyclophosphamide. Gynecol Oncol. 1976;4(1):43-52.
Swerdlow SH. International Agency for Research on Cancer, World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer; 2008.
Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol: Off J Am Soc Clin Oncol. 1999;17(4):1244.
Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet Lond Engl. 2002;359(9318):1686-1689.
Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2003;102(6):1989-1996.
Rivell GL, Brunson CY, Milligan L, et al. Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents. Am J Hematol. 2011;86(8):699-701.
Fu D, Calvo JA, Samson LD. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer. 2012;12(2):104-120.
Remberger M, Törlen J, Serafi IE, et al. Toxicological effects of fludarabine and treosulfan conditioning before allogeneic stem-cell transplantation. Int J Hematol. 2017;106(4):471-475.
Hong JY, Yoon DH, Suh C, et al. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis. Ann Hematol. 2018;97(8):1437-1443.
Dixit S, Baker L, Walmsley V, Hingorani M. Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review. Anticancer Drugs. 2012;23(10):1099-1106.
Kastan MB, Schlaffer E, Russo JE, et al. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood. 1990;75(10):1947-1950.
Gilbar PJ, Richmond J, Wood J, Sullivan A. Syndrome of inappropriate antidiuretic hormone secretion induced by a single dose of oral cyclophosphamide. Ann Pharmacother. 2012;46(9):e23.
Hwang S-B, Lee H-Y, Kim H-Y, et al. Life-threatening acute hyponatremia with generalized seizure induced by low-dose cyclophosphamide in a patient with breast cancer. J. Breast Cancer. 2011;14(4):345-348.
Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808.
Chow VA, Shadman M, Gopal AK. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. Blood. 2018;132(8):777-781.
Goebeler M-E, Knop S, Viardot A, et al. Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol: Off J Am Soc Clin Oncol. 2016;34(10):1104-1111.
Pfeifer M, Zheng B, Erdmann T, et al. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia. 2015;29(7):1578-1586.
Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544.
Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol: Off J Am Soc Clin Oncol. 2015;33(6):540-549.
North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med. 1982;155(4):1063-1074.